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Abstract
Objective—To evaluate long-term clinical and economic outcomes of naproxen, ibuprofen, 
celecoxib or tramadol for OA patients with cardiovascular disease (CVD) and diabetes.
Design—We used the Osteoarthritis Policy Model to examine treatment with these analgesics 
after standard of care -- acetaminophen and corticosteroid injections -- failed to control pain. 
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NSAID regimens were evaluated with and without proton pump inhibitors (PPIs). We evaluated 
over-the-counter (OTC) regimens where available. Estimates of treatment efficacy (pain reduction, 
occurring in ~ 57% of patients on all regimens) and toxicity (major cardiac or gastrointestinal 
toxicity or fractures, risk ranging from 1.09% with celecoxib to 5.62% with tramadol) were 
derived from published literature. Annual costs came from Red Book Online®. Outcomes were 
discounted at 3%/year and included costs, quality-adjusted life expectancy, and incremental cost-
effectiveness ratios (ICERs). Key input parameters were varied in sensitivity analyses.
Results—Adding ibuprofen to standard of care was cost saving, increasing QALYs by 0.07 
while decreasing cost by $800. Incorporating OTC naproxen rather than ibuprofen added 0.01 
QALYs and increased costs by $300, resulting in an ICER of $54,800/QALY. Using prescription 
naproxen with OTC PPIs led to an ICER of $76,700/QALY, while use of prescription naproxen 
with prescription PPIs resulted in an ICER of $252,300/QALY. Regimens including tramadol or 
celecoxib cost more but added fewer QALYs and thus were dominated by several of the naproxen-
containing regimens.
Conclusions—In patients with multiple comorbidities, naproxen- and ibuprofen-containing 
regimens are more effective and cost-effective in managing OA pain than opioids, celecoxib or 
standard of care.
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INTRODUCTION
Symptomatic knee osteoarthritis (OA) affects over 9.3 million adults, leading to $27 billion 
in health care expenditures annually in the US.1, 2 Pharmacologic treatment for knee OA 
generally begins with acetaminophen and proceeds to non-steroidal anti-inflammatory drugs 
(NSAIDs) and intra-articular corticosteroid injections.3-6 Physicians are cautious about 
using NSAIDs and cyclooxygenase 2 (COX-2) inhibitors in patients with multiple 
comorbidities because of these agents’ toxicities.3, 7-9 Yet, despite concerns about toxicity 
and illicit diversion,10-12 opioid use for knee OA has increased significantly in the past 
decade.11, 13
Comorbidities affect up to 40% of knee OA patients13 and increase toxicity of NSAIDs and 
opioids.3, 14 Thus, clinicians are unsure whether to prescribe these medications to patients 
with OA and comorbidities. Nevertheless, over $500 million is spent annually in the US on 
opioids for such OA patients.1, 13, 15 OA treatment guidelines are ambiguous on the role of 
NSAIDs and opioids in this setting.3-5 Osteoarthritis Research Society International 
(OARSI) guidelines classify use of oral NSAIDs as “uncertain” in patients with moderate 
comorbidities and “inappropriate” in those with severe comorbidities. These guidelines 
classify opioid use as “uncertain” in all OA patients.3 The American Academy of 
Orthopedic Surgeons (AAOS) OA treatment guidelines provide a strong recommendation 
for NSAIDS and tramadol, but an inconclusive recommendation for acetaminophen.4 The 
American College of Rheumatology OA treatment guidelines provisionally recommend 
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tramadol and provisionally do not recommend other opiates.5 Neither the AAOS nor 
American College of Rheumatology distinguishes recommendations for older patients.
We evaluated long-term clinical and economic outcomes of incorporating naproxen, 
ibuprofen, celecoxib or tramadol in the treatment of patients with knee OA and multiple 
comorbidities. Additionally, since ibuprofen and naproxen are available over-the-counter 
(OTC) and proton pump inhibitors (PPIs) are often used in high-risk patients, we evaluated 
long-term clinical benefits and costs associated with OTC use of ibuprofen and naproxen 
and with addition of OTC and prescription PPIs to regimens involving NSAIDs.
METHODS
Analytic Overview
We used the Osteoarthritis Policy (OAPol) Model 16, 17 to examine the cost-effectiveness of 
prescription and OTC naproxen with and without PPIs, prescription and OTC ibuprofen with 
and without PPIs, celecoxib with and without PPIs and tramadol in persons with knee OA, 
cardiovascular disease (CVD) and diabetes. The primary outcomes were quality-adjusted 
life years (QALYs) and lifetime medical costs. The cost-effectiveness of each strategy was 
assessed as recommended by the US Panel on Cost-Effectiveness in Health and Medicine.18 
We defined incremental cost-effectiveness ratios (ICERs) as the ratio of change in costs to 
change in QALYs of two consecutive strategies, ranked by cost. We discounted costs and 
QALYs by 3% annually.18 Treatment strategies that decreased QALYs while increasing 
costs relative to an alternative strategy were termed dominated. We compared ICERs to a 
threshold societal willingness to pay (WTP) for medical interventions of $100,000/
QALY.19-21
The OAPol Model
The OAPol Model is a Monte Carlo simulation model of the natural history and 
management of knee OA.16, 17 It forms simulated cohorts of knee OA patients based on 
distributions of demographic and clinical characteristics, including OA severity, obesity, and 
comorbidities (CVD, diabetes mellitus, chronic obstructive pulmonary disease and other 
musculoskeletal disorders).22-24 These are the most common comorbidities that have an 
influence on life expectancy and quality of life.25, 26 Pain severity in the OAPol Model is 
assessed by the Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) Pain subscale (range 0-100, with 100 worst) and is subsequently categorized 
into 5 groups: no pain (0-1), mild pain (2-15), moderate pain (16-40), severe pain (41-70), 
and extreme pain (71-100).27-29 Upon OA development, subjects are assigned a pain 
severity value and corresponding pain group. Each year subjects may develop new 
comorbidities, progress in pain severity, increase BMI, and/or die. The model follows each 
subject until death, allowing subjects to transition between health states and to accumulate 
medical costs (OA and non-OA related) and quality of life (QoL) decrements. Factors 
governing these transitions are detailed in prior publications and the Technical 
Appendix.2, 16 QoL decrements (utilities) reflect preference valuation for particular health 
states, estimated from 0.0 to 1.0 where 1.0 represents perfect health and 0.0 death.30 QoL 
utilities are assigned based on obesity, pain severity, age, and comorbidities. Annual 
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underlying costs are incorporated to capture non-OA related management and are assigned 
based on age, obesity status, and number of comorbidities.31-33 Each treatment is 
characterized by its pain relief, toxicity and cost profile. Toxicities are classified as major or 
minor, each carrying specific costs and QoL decrements. Major toxicities lead to treatment 
discontinuation and carry a probability of death.
Treatment Strategies
We examined fourteen treatment strategies. The first is standard of care (SOC), which, 
reflecting treatment guidelines,3, 5 includes physical therapy, acetaminophen and 
corticosteroid injections. The remaining strategies are implemented if SOC does not relieve 
pain (Figure 1). Naproxen-containing strategies include: prescription naproxen (naproxen 
Rx), over-the-counter naproxen (naproxen OTC), naproxen with a proton pump inhibitor 
(naproxen Rx +PPI Rx), naproxen OTC + PPI OTC and naproxen Rx + PPI OTC. Ibuprofen 
strategies include: ibuprofen Rx, ibuprofen OTC, ibuprofen Rx + PPI Rx, ibuprofen OTC + 
PPI OTC, and ibuprofen Rx + PPI OTC. We tested two celecoxib strategies (celecoxib Rx 
and celecoxib Rx + PPI Rx) and one tramadol strategy. We chose ibuprofen and naproxen 
because they are the most commonly used NSAIDs among patients with knee OA; celecoxib 
because of its frequency of use and putatively lower gastrointestinal toxicity; and tramadol 
because of its frequency of use in this high-risk setting.3, 13, 34 The doses of each agent are 
provided in Section 3.2 of the Technical Appendix.
Subjects could exit pharmacologic regimens via three pathways: 1) lack of analgesic 
efficacy, 2) major toxicity, or 3) voluntary discontinuation for other reasons including minor 
toxicity (nausea, constipation, somnolence, and dyspepsia). Lack of efficacy in the first year 
was defined as failure to decrease pain by at least one pain group. In all subsequent years, 
lack of efficacy was defined as failing to maintain the pain relief achieved in the first year on 
the regimen. Major toxicities included cardiovascular (CV) events (myocardial infarction, 
stroke, heart failure), gastrointestinal (GI) events (upper or lower GI bleed, bowel 
obstruction) and fractures (hip, upper or lower extremities).35 Each category of major 
toxicity was associated with a unique cost, mortality, and QoL decrement; major toxicity 
also led to discontinuation. If the treatment strategy did not alleviate pain or was associated 
with major toxicity, patients were treated with medications to try to manage pain and 
became eligible for total knee arthroplasty (TKA). If the patient experiences toxicity or lack 
of efficacy with one of the regimens, he or she is treated with acetaminophen as needed until 
the patient is offered TKR. Because this is a high risk population, we do not switch the 
patient from one NSAID to another or to tramadol, as one might in a lower risk group. This 
period on acetaminophen as needed generally lasts about 13 years.2
TKA recipients were at risk for revision if the primary TKA failed. Eligibility for TKA was 
governed by radiographic and symptomatic OA severity. The proportion of eligible patients 
offered a regimen and the proportion of those offered who accepted were stratified by 
subjects’ age, race, and sex.
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Input Data
Cohort characteristics—The cohort had mean age 74 (SD 12), 62% were female, and 
47% had BMI > 30 kg/m2. Race/ethnicity, sex, and obesity distributions were derived from 
the National Health Interview Survey (NHIS) 2012.36 Cohort demographics, costs, and QoL 
utilities are presented in Table 1. Costs are presented in 2013 US dollars – the most recent 
year in which all costs are available.
Analgesics’ characteristics—The efficacy of each regimen was defined by the 
reduction in pain achieved by subjects on the regimen in the first year of treatment. Pain 
reduction was represented by the absolute decrease in pain severity over the course of the 
first year as assessed by WOMAC Pain subscale (range 0-100, with 100 worst).27 If the 
absolute reduction in pain severity led a subject to decrease in pain group, the regimen was 
considered efficacious.
This efficacy parameter was stratified by pain severity upon entering the regimen. Following 
review of the relevant published literature, efficacy was derived using meta-analytic 
techniques.37 Major toxicities were classified as cardiovascular (CV), gastrointestinal (GI), 
or fracture events. Lacking long-term data, we assumed the rates of major toxicity events in 
subsequent years of treatment were one-half the rate in the first year, reflecting removal of 
those experiencing toxicities in the first year.35, 38 We tested this assumption in sensitivity 
analyses. Minor toxicities varied by drug class and included nausea, somnolence, 
constipation, and dyspepsia.39-42
To estimate the annual cost of each drug we converted Average Wholesale Prices (AWPs) 
listed in Red Book Online® to Average Sales Prices (ASPs), by reducing brand name and 
generic drug costs by 26% and 68% respectively.15, 43 The final drug cost was estimated by 
weighting ASPs of brand name drugs as 7% and generic drugs as 93%, reflecting the 
proportion of prescriptions filled with branded and generic drugs respectively.44 Additional 
details on derivations of efficacy, toxicity, and cost attributable to each regimen are 
presented in the Technical Appendix. The next paragraphs summarize specific 
characteristics for each of the analgesics.
NSAIDs
Efficacy: We used meta-analytic techniques to derive a mean WOMAC Pain change of 20.0 
points for all NSAID regimens. Further details on the derivation of pain decrements 
associated with NSAIDs are presented in Section 2 of the Technical Appendix. Because 
OTC analgesics are not available in the same doses as their prescription counterparts, we 
reduced the efficacy of OTC regimens in a dose-dependent fashion, resulting in a 12% 
reduction from 20.0 points and resulting in a mean change in WOMAC Pain of 17.6 points. 
All NSAIDs were associated with a 24% likelihood of failing to maintain pain relief in 
subsequent years of treatment.17, 41
Toxicity: Prescription naproxen major toxicity included GI events with a likelihood of 
1.59% in the first year of treatment and associated mortality of 11.60%.45, 46 The addition of 
PPIs reduced the probability of major GI events to 0.56%.45, 47 Major toxicity of celecoxib 
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included CV and GI events, with likelihoods of 0.70% and 0.40%, respectively, in the first 
year.45 Adding PPIs reduced celecoxib’s major first year GI toxicity to 0.14%.45, 47 
Celecoxib major toxicity was associated with mortality of 20.03%.45, 46
Prescription ibuprofen was associated with CV and GI events with first year probabilities of 
0.90% and 1.49% respectively.45 Incorporating PPIs reduced first year GI toxicity to 
0.53%.45, 47 For prescription-based NSAID regimens, we applied a 63% likelihood of 
experiencing a minor toxicity in all treatment years.41, 42 Minor toxicities did not lead to 
death or discontinuation. We reduced the toxicity of OTC NSAID regimens by 12% in the 
base case. Based on data from multiple randomized trials of NSAIDs, we derived an 11.28% 
probability of discontinuation (for minor toxicity) within the first year of all prescription 
NSAID regimens.48-52
Cost: Costs of $900, $400, and $3,700 were applied annually for prescription naproxen, 
prescription ibuprofen, and celecoxib respectively, which included costs of the analgesic, 
complete blood count, electrolyte tests and office visits.15, 43, 44, 53, 54 We included two 
office visits with laboratories, reflecting the need to monitor patients with comorbidities 
closely. We added $700 to the cost of each regimen with prescription PPIs.15, 43, 44 OTC 
naproxen and ibuprofen regimens were associated with an annual cost of $400, with an 
additional $300 added to regimens incorporating OTC PPIs.15, 55
Tramadol
Efficacy: Estimated mean WOMAC pain change for tramadol was 21.2 points. Further 
details on the derivation of pain decrements associated with tramadol are presented in 
Section 2 of the Technical Appendix. We assigned a 24% likelihood of failing to maintain 
pain relief in subsequent years (similar to that of NSAIDs).41
Toxicity: Tramadol treatment was associated with major (fractures) and minor toxicities 
(nausea, constipation, and somnolence). We applied a 5.62% likelihood of developing a 
fracture within the first year and 2.85% in subsequent years for the base case.56 Fractures 
were associated with mortality of 8.88%.56-58 The risks, costs and QOL decrements 
associated with tramadol minor toxicities are provided in the Technical Appendix. We 
assumed a 22% likelihood of tramadol discontinuation due to minor toxicity, applied in the 
first year of treatment.59, 60 Because prior literature documents that opioid-treated subjects 
have worse TKA outcomes than subjects not using opioids prior to TKA,61, 62 we assigned a 
10% relative increase in the probability of early revision and 10% relative reduction in pain 
relief in the first year following surgery for opioid treated persons.61, 62
Cost: We derived annual costs of $900 for the tramadol regimen, which included the cost of 
tramadol and biannual office visits.15, 43, 44, 53, 54
Sensitivity Analyses
We performed one- and two-way sensitivity analyses to assess the impact of uncertainty in 
essentially all efficacy and toxicity parameters on cost-effectiveness estimates. We also 
varied the cost of prescription naproxen by varying the proportion of analgesic cost due to 
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brand name agents. The base case is 7%, and we varied the proportion from 0 to 10%. We 
simultaneously varied the efficacy and toxicity of OTC-based regimens from 20% reduction 
to 20% increase relative to the prescription-based regimens. We further assessed the impact 
of truncating efficacy for analgesic regimens at 3 years. We used probabilistic sensitivity 
analyses to evaluate the effects of simultaneously varying the efficacy and major toxicity of 
all regimens. Results of the probabilistic sensitivity analysis are depicted by cost-
effectiveness acceptability curves, which illustrate the probability that alternative treatment 
strategies are cost-effective at various WTP thresholds.63, 64
RESULTS
Base Case Analysis
Figure 2 shows the relationship between total lifetime costs and discounted quality-adjusted 
life expectancy (QALE) for all 14 strategies. Strategies involving naproxen were 
consistently more effective and more cost-effective than those involving tramadol and 
celecoxib and most involving ibuprofen. These points are illustrated by the efficiency 
frontier (Figure 2), which depicts the greatest QALE that can be achieved for any given 
outlay. Strategies that lie along this frontier are termed ‘efficient.’ The tramadol- and 
celecoxib-based strategies were dominated. That is, they cost more and led to lower clinical 
benefits than one or more of the naproxen-based strategies.
Table 2 presents costs, QALE and proportion of patients undergoing TKA for each of 14 
strategies. The four non-dominated (efficient) strategies are highlighted in grey. SOC led to 
an estimated discounted QALE of 6.49 QALYs with an associated discounted lifetime cost 
of $135,800. Addition of prescription ibuprofen was cost saving compared to SOC, 
increasing the QALE to 6.56 QALYs and decreasing cost to $135,000. OTC naproxen led to 
a QALE of 6.57 QALYs and a discounted lifetime cost of $135,300, resulting in an ICER of 
$54,800/QALY compared to prescription ibuprofen. Using prescription naproxen with OTC 
PPIs increased the QALE to 6.59 and cost to $137,300. As compared with the costs and 
QALE associated with naproxen OTC, the ICER was $76,700/QALY. The table also shows 
that the lifetime risk of TKA associated with these strategies was generally inversely 
proportional to the QALE; strategies with the worst QALE (such as standard of care) had the 
highest TKA rates (38%) while the NSAID and PPI regimens had the highest QALE and 
lowest TKA rates (~ 32%).
Sensitivity Analyses
All regimens were evaluated under a range of toxicity and efficacy values (Figures 3a and 
b). The base case assumed a 12% reduction in efficacy and toxicity of OTC naproxen 
relative to prescription naproxen. Assuming a 20% reduction in efficacy of naproxen OTC 
(vs. prescription) led to a reduction in QALE of the naproxen OTC regimen relative to 
prescription ibuprofen. Naproxen OTC with these characteristics was dominated by 
prescription ibuprofen (Figure 3a). When we applied a 10% relative reduction in naproxen 
OTC (vs. prescription) efficacy, the ICER for naproxen OTC was less than $50,000/QALY 
as long as the toxicity was less than that of prescription naproxen. The ICER of naproxen 
OTC with OTC PPIs regimen remained less than $100,000/QALY when the toxicity was 
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greater than prescription naproxen and the efficacy remained within 10% of the prescription-
based regimen (Figure 3b). Truncating efficacy at 3 years had no impact on cost-
effectiveness estimates.
We evaluated the effects of simultaneously varying efficacy, major toxicity, and relative 
decrement in efficacy and toxicity for OTC analgesics through probabilistic sensitivity 
analyses. At a WTP of $50,000/QALY, naproxen OTC had 74% likelihood of being the 
cost-effective regimen. At a WTP of $100,000/QALY, prescription naproxen with PPI OTC 
had 41% likelihood of being the most cost-effective treatment strategy, naproxen OTC and 
PPI OTC had 35% likelihood and prescription naproxen alone had a 17% likelihood. 
Increasing the WTP threshold to $150,000/QALY resulted in prescription naproxen with 
PPI OTC being the most cost-effective strategy 60% of the time, and naproxen with PPI 
OTC 32% of the time (Figure 4).
DISCUSSION
Pain management in knee OA patients with multiple comorbidities is costly and requires a 
delicate balance of pain relief and toxicity. We used the OAPol Model to evaluate the cost 
effectiveness of incorporating naproxen, ibuprofen, celecoxib or tramadol into the treatment 
of these patients. At a willingness-to-pay threshold of $100,000/QALY, prescription 
naproxen with PPI OTC appears cost-effective with an ICER of $76,700/QALY. This 
finding persists even when naproxen toxicities are assumed to be 20% higher than those 
documented in published studies. Probabilistic sensitivity analyses show that at a WTP 
threshold of $100,000/QALY, prescription naproxen and naproxen OTC with PPI OTC also 
appear attractive from a cost-effectiveness standpoint. More generally, we found that several 
naproxen-based regimens are cost-effective, while tramadol, celecoxib and standard of care 
are not.
Tramadol’s higher rates of toxicity and discontinuation led to smaller gains in QALYs than 
NSAID regimens while Celecoxib’s higher cardiac toxicity led to smaller gains than most 
naproxen regimens. Celecoxib was the most costly regimen. Consequently, both tramadol 
and celecoxib were dominated by NSAID-based regimens. Naproxen’s lack of cardiac 
toxicity45 resulted in its providing greater clinical benefit and cost-effectiveness than 
ibuprofen.
To our knowledge, this contribution is unique. It is the first cost-effectiveness analysis of 
analgesic strategies in knee OA patients with comorbidities and the first to incorporate 
opioids or evaluate OTC regimens. A cost-utility analysis of celecoxib and rofecoxib in 
patients with OA or rheumatoid arthritis reported that in high-risk patients ibuprofen with 
PPIs was dominated by celecoxib while diclofenac with PPIs had an ICER of $298,400/
QALY.54, 65, 66 This analysis was conducted with a five-year perspective, excluded a 
standard of care comparator and did not consider cardiovascular toxicity, an important factor 
in our analysis. A comparison of COX-2 selective and non-selective NSAIDs, and non-
selective NSAIDs with PPIs, concluded that in average-risk patients, NSAIDs with PPIs are 
unlikely to be cost-effective, while in patients at high risk for ulcers, NSAIDs with PPIs 
were preferred.67
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We acknowledge several limitations. Since analgesic trial duration ranges from 2-12 weeks, 
our estimates of longer-term efficacy and toxicity relied upon expert clinician opinion. We 
did not address acetaminophen toxicity,68 as it is substantially lower than NSAID and 
opioids toxicity and thus would influence our results minimally.3 The findings we present 
pertain to older OA patients with multiple comorbidities and should not be generalized to 
the broader OA population. We focus on tramadol because of its wide use and lower toxicity 
than more potent opioids. Our findings should not be generalized to the entire class of 
opioids. We acknowledge that clinicians may switch from agent to agent in some patients 
due to inefficacy or toxicity. Our findings can be useful in prioritizing the order of 
medications in these circumstances. Finally, we note that more potent opioids may be 
diverted to illicit use, leading to societal costs exceeding $63 billion across all users.10, 69 
Since tramadol contributes little to opioid abuse, we did not consider diversion.70, 71
This work presents important implications for research, policy, and practice. To overcome 
the limitations of short term studies, we urgently need studies on the long-term efficacy, 
toxicity and costs of analgesics. From a policy perspective, over $500 million is spent on 
opioids in patients with OA and comorbidities.1, 13, 15 Our results suggest that for older 
individuals with comorbidities, tramadol provides less benefit than naproxen-containing 
regimens. Policy makers could consider limiting tramadol use in this setting to patients with 
contraindications, intolerance or failure to respond to NSAIDs. From a clinical perspective, 
our findings challenge the reluctance of physicians to use non-selective NSAIDs in patients 
with multiple comorbidities. Our findings indicate that no treatment, tramadol and celecoxib 
are poor choices in this setting, whereas naproxen (prescription or OTC) with PPI OTC or 
prescription naproxen alone can be recommended as cost-effective regimens in older 
patients with knee OA and cardiovascular disease and diabetes.
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Figure 1. Treatment Sequences for OA Management
This figure depicts the treatment sequences evaluated. Shaded cells indicate a contrast to the 
standard of care sequence. For each regimen assessing NSAIDs (naproxen, ibuprofen, and 
celecoxib), an additional regimen incorporating PPIs was evaluated. Further, for naproxen 
and ibuprofen regimens, over-the-counter based sequences were assessed.
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Figure 2. Cost-effectiveness of all treatment strategies
This figure portrays the cost-effectiveness of alternative prescription- and over-the-counter-
based treatment strategies for OA patients with multiple comorbidities. The efficiency 
frontier (solid line) defines the greatest QALE that can be achieved for any given outlay. 
Strategies that lie along this frontier are termed ‘efficient.’
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Figure 3. Incremental Cost-Effectiveness Ratios of Over-the-Counter Regimens of (a) Naproxen 
and (b) Naproxen + PPI
Figure 3 shows the results of a “two-way sensitivity analysis.” This figure illustrates the 
ICERs calculated for (a) the naproxen over-the-counter (OTC) regimen and (b) OTC 
naproxen with PPIs regimens, under a range of values for regimen efficacy and toxicity. The 
purpose of the analysis is to examine the effect on cost-effectiveness (measured in ICERs) 
of differences in efficacy and toxicity of OTC vs. prescription naproxen. The horizontal axis 
shows changes in efficacy of OTC naproxen as compared with prescription naproxen. The 
vertical axis shows changes (increases or reductions) in toxicity of the regimen compared to 
prescription naproxen. The shading denotes the ICER, ranging from light yellow (ICERs < 
$25,000/QALY) to black (dominated, indicating greater cost and lower efficacy than the 
comparator). In panel (a) the OTC naproxen regimen is compared to prescription ibuprofen. 
In panel (b) OTC naproxen with PPIs is compared to OTC naproxen (without PPIs). In both 
instances, the base case, using the initial input assumptions, is marked with an asterisk.
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Figure 4. Probability of cost-effectiveness of alternative treatment strategies at each WTP 
threshold
The probability of cost-effectiveness of prescription naproxen with either prescription or 
OTC PPIs is shown. These results are based on 100 iterations, varying the efficacy of all 
regimens, probability of prescription naproxen major toxicity, and the toxicity of OTC 
agents. The probability of cost-effectiveness of prescription naproxen with OTC PPIs 
reaches 60% if the WTP threshold is $150,000/QALY.
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Table 1
Model Inputs
Parameter Estimate
Data Source Used in
Derivations
Cohort Characteristics
Demographics Mean (SD)
Assumption
US Census Bureau
201272
NHIS 201236
Mean Age 74 (12)
Percent Female 62%
WOMAC Pain 60 (10)
Nonobese/Obese
Osteoarthritis Initiative73
Brazier et al. 200430
Quality of Life Utilities WOMAC Pain (0-100)
Age Group 16 - 40 41 - 70 71 - 100
65-74 0.762/0.751
0.665/
0.654
0.530/
0.519
75+ 0.745/0.734
0.648/
0.637
0.513/
0.502
Underlying Medical
Costs* Comorbidities
MCBS 200934
NHANES 2009-201074
Red Book Online®15
CPI54
Age group 0-1 2-3 4+
70-74 $5,300 $10,700 $16,200
75-79 $6,200 $11,600 $17,100
80+ $8,200 $13,500 $19,100
Treatment Characteristics
Tramadol Naproxen Ibuprofen Celecoxib Data Source Used in
DerivationsRx OTC Rx OTC
Annual Cost * $900 $900 $400 $400 $400 $3,700 Red Book Online®15,
CPI54, Levinson et al.
200543, IMS 201144
Bronnenberg et al.
201355
Medicare Physician Fee
Schedule 2012B53
Medicare Clinical
Diagnostic Laboratory
Fee Schedule 201275
Bhala et al. 199945
Bensen et al. 199942
Scott et al. 200041
Silverstein et al. 200048
Chan et al. 201049
Schnitzer et al. 200452
Cannon et al. 200650
Lisse et al. 200351
Miller et al. 201156
Efficacy
Mean (SD) WOMAC
Pain Reduction in First
Year of Treatment
21 (21) 20 (17) 18 (17) 20 (17) 18 (17) 20 (17)
Adverse Effects
Minor Toxicity 73.62% 63.00% 51.19% 63.00% 51.19% 63.00%
Major Toxicity 5.62% 1.59% 1.39% 2.39% 2.08% 1.09%
Gastrointestinal - 1.59% 1.39% 1.49% 1.30% 0.40%
Cardiovascular - - - 0.90% 0.78% 0.70%
Fracture 5.62% - - - - -
Discontinuation due to
minor toxicity 22.00% 11.28% 10.42% 11.28% 10.42% 11.28%
Proton Pump Inhibitors
Rx OTC
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Parameter Estimate
Data Source Used in
Derivations
Annual Cost* $700 $300
Red Book Online®15,
Bronnenberg et al.
201355
Rostom et al. 200047
Efficacy
Percent Reduction in
NSAID-induced GI
Events
65% 60%
Abbreviations: OA, osteoarthritis; K-L Kellgren-Lawrence grade; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; 
PPIs, Proton Pump Inhibitors; NHIS, National Health Interview Survey; NHANES National Health and Nutrition Examination Survey; MCBS, 
Medicare Current Beneficiary Survey; CPI, Consumer Price Index; Rx, prescription; OTC, over-the-counter
*Costs are in 2013 US Dollars.
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Table 2
Cost-effectiveness of prescription- and OTC-based regimens
Regimen QALE COST ICER* %TKA Utilization
Standard of Care 6.485 $135,800 37.56%
Ibuprofen Rx 6.559 $135,000 Cost Saving 31.53%
Ibuprofen OTC 6.547 $135,200 Dominated 31.78%
Naproxen OTC 6.566 $135,300 $54,800 31.81%
Ibuprofen Rx + PPI OTC 6.569 $135,800 Extended Dominance 31.49%
Ibuprofen OTC + PPI OTC 6.558 $136,000 Dominated 31.76%
Naproxen OTC + PPI OTC 6.575 $136,100 Extended Dominance 31.76%
Naproxen Rx 6.580 $136,500 Extended Dominance 31.57%
Tramadol 6.492 $136,600 Dominated 32.15%
Ibuprofen Rx + PPI Rx 6.570 $136,700 Dominated 31.51%
Naproxen Rx + PPI OTC 6.591 $137,300 $76,700 31.54%
Naproxen Rx + PPI Rx 6.595 $138,200 $252,300 31.51%
Celecoxib 6.563 $142,500 Dominated 32.11%
Celecoxib + PPI 6.566 $144,100 Dominated 32.11%
This table shows the quality adjusted life expectancy (QALE), cost, incremental cost effectiveness ratios (ICERs) and utilization of TKA in each 
cohort. Strategies are ordered by cost. The ICER is calculated as the difference in cost between two strategies divided by the difference in quality 
adjusted life expectancy. These comparisons are made between a given strategy and the prior, non-dominated strategy. By convention, a strategy is 
labeled “dominated” if it costs more and delivers fewer benefits than some other strategy; a strategy is labeled “weakly dominated” (also called 
extended dominance) if it costs more and delivers fewer benefits than a combination of two other strategies. For example, the ICER for Naproxen 
Rx + PPI OTC is calculated as the difference in cost /difference in QALE between that strategy and Naproxen OTC. The QALE and cost data 
presented in the table are rounded while the ICERs are calculated precisely using unrounded parameters. Thus, the ICER’s presented are slightly 
different from those derived from the QALE and cost data in the table.
Abbreviations: QALE, quality adjusted life expectancy; ICER, incremental cost-effectiveness ratio; TKA, total knee arthroplasty; PPI, proton 
pump inhibitor; Rx, prescription; OTC, over-the-counter
*
ICERs reported as incremental costs in 2013 USD per QALY gained compared to the alternative treatment.
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